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co-immunoprecipitation experiments. Furthermore, appli-
cation of sigma-1 drugs to the cells reduced the surface 
expression of nNav1.5 protein, which could explain how 
sigma-1 receptor activation could alter the metastatic 
behaviour of breast cancer cells. Overall, these results are 
consistent with the idea of a sigma-1 protein behaving like 
either a “chaperone” or a regulatory subunit associated with 
nNav1.5.
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Introduction
Sigma receptors show an unusual promiscuous ability to 
associate with a surprisingly large number of critical cel-
lular components. These include the IP3 receptor in endo-
plasmic reticulum, voltage sensitive ion channels and the 
cytoskeletal element ankyrin (for review, see Aydar et al. 
2004). The sigma-1 receptor is a transmembrane protein 
that has been reported to be localised to the plasma mem-
brane, perinuclear areas, endoplasmic reticulum and in 
regions of cell-to-cell communication (Aydar et al. 2004). 
The protein has two transmembrane regions and two ster-
oid-binding domains. The latter forms a pocket that serves 
as a binding site for cholesterol, steroids and sphingolipids 
(Palmer et al. 2007; Fontanilla et al. 2009). A wide range of 
synthetic or natural compounds (‘sigma ligands’), includ-
ing opiates, antipsychotics, psychostimulants, alkaloids 
and antidepressants, also bind to sigma-1 receptors (Palmer 
et al. 2008; Maurice and Su 2009). In vivo, endogenous 
dimethyltryptamine (DMT) interacts with sigma-1 recep-
tors in the brain but the physiological significance of this 
is not clear (Fontanilla et al. 2009; Mavlyutov et al. 2012). 
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The drug SKF10047 has been utilised extensively as a 
sigma-1 ligand and has significant preference for sigma-1 
over sigma-2 receptors (Aydar et al. 2004). Importantly, 
sigma-1 has pathophysiological importance (Tsai et al. 
2009).
Studies on sigma-1 receptor modulation of ion chan-
nels have deduced the signal transduction mechanism of 
sigma-1 receptors (1) to be membrane delimited; (2) to be 
independent of G-protein coupling and protein phospho-
rylation (Lupardus et al. 2000); (3) to be reconstitutable 
in a heterologous system (Aydar et al. 2002); (4) not to 
require cytoplasmic factors (Lupardus et al. 2000); (5) to 
necessitate the receptor and the ion channel to be in close 
proximity, probably to form a stable macro-molecular com-
plex (Aydar et al. 2002). Modulation of the heart voltage-
gated Na+ channel (Nav1.5) by sigma-receptors was dem-
onstrated and this could be an important pathway through 
which drugs could alter cardiac excitability and rhythmicity 
(Johannessen et al. 2011). This was further corroborated by 
atomic force microscopy imaging of complexes between 
sigma-1 receptors and Nav1.5 channels revealing a fourfold 
symmetry (Balasuriya et al. 2012). In human breast cancer 
(BCa) MDA-MB-231 cells, which functionally express the 
voltage-gated sodium channel (VGSC) subtype Nav1.5, 
sigma-1 receptor was found to regulate current density, 
suggesting a functional interaction between the two pro-
teins (Balasuriya et al. 2012). Despite such advances, how-
ever, the exact cellular mechanism of sigma-1 receptor 
action is still unclear and further experiments are required 
to clarify their role in physiological and pathophysiologi-
cal cell signalling (Tsai et al. 2009). A model has been 
proposed in which the sigma-1 receptors are “silent” under 
normal physiological conditions, whereas in disease, the 
receptor behaves as a chaperone that binds ‘client’ proteins, 
modulates cellular activity and promotes survival (Su et al. 
2010). This hypothesis has received some support from 
studies demonstrating that sigma-1 silencing would sup-
press recovery after experimental stroke (Ruscher et al. 
2011) and promote retinal degeneration after acute damage 
to the optic nerve (Mavlyutov et al. 2012).
The role that sigma-1 receptors play in cancer is not 
clear, although it is frequently up-regulated in human can-
cer cells and tissues (Aydar et al. 2004, 2006). The most 
in-depth study on the role that sigma-1 receptors play in 
BCa was performed by Palmer et al. (2007). The results 
indicated that cancer cells express high levels of sigma-1 
receptors compared with corresponding normal cells. 
Localisation of the sigma-1 receptor was investigated in 
MDA-MB-231 cells by immunocytochemistry and confo-
cal microscopy. Expression was predominantly at the cell 
periphery but also in the endoplasmic reticulum (Palmer 
et al. 2007). Both sigma-1 and sigma-2 drugs and a 
sigma-1 receptor silencing construct reduced proliferation 
and adhesion of BCa cell lines compared to a non-cancer-
ous BCa cell line. The effect on adhesion was found to be 
through a functional interaction with β-1 integrin (Palmer 
et al. 2007). Although the exact nature of how sigma-1 
receptors could modulate adhesion and migration in BCa 
cells has not been determined, it has been suggested that 
voltage-gated sodium channels (VGSCs) known to be 
expressed in BCa cells could play an important role (Aydar 
et al. 2004). Several studies have shown that functional 
VGSC expression occurs in a variety of carcinomas and 
promotes metastatic behaviour. Such carcinomas include 
BCa (Fraser et al. 2005) as well as cancers of the prostate 
(Grimes et al. 1995; Laniado et al. 1997; Nakajima et al. 
2009), lung (Onganer and Djamgoz 2005; Campbell et al. 
2013), colon (House et al. 2010) and cervix (Diaz et al. 
2007). It has been suggested, therefore, (1) that VGSC 
up-regulation is an early event in metastatic progression 
and (2) that VGSC expression is a ‘switch,’ necessary 
and sufficient for engaging cancer cells in a highly inva-
sive state. Importantly, in BCa and colon cancer the pre-
dominant VGSC was found to be the neonatal splice vari-
ant of Nav1.5 (nNav1.5) and this has been proposed to be 
a novel mechanism targetable with small-molecule drugs, 
monoclonal antibody and natural neurotoxins (Onkal and 
Djamgoz 2009).
The aims of this study were (1) to investigate a possible 
functional link between sigma-1 receptors and nNav1.5 in 
BCa cells and (2) to test the possibility that the effects of 
sigma-1 drugs in altering the metastatic properties of BCa 
cells could occur via modulation of nNav1.5.
Methods
Cell culture
Human BCa cell lines (MDA-MB-468, MDA-MB-231 
and MDA-MB-453) were obtained from the American 
Type Culture Collection and cultured in DMEM (Life 
Technologies) containing 5 % foetal bovine serum (FBS) 
and 4 mmol/l glutamine with penicillin-streptomycin. All 
cell lines were maintained in a 37 °C CO2 incubator in 
100-mm culture dishes. Cells prepared for electrophysi-
ological analysis were cultured without the addition of 
penicillin-streptomycin.
Pharmacological agents
Sigma-1 receptor ligands SKF10047 and 5-methyl-
dimethytryptamine (5-CH3-DMT) were obtained from 
Sigma-Aldrich and diluted to a stock concentration of 
10 mM in a 50/50 mixture of water/ethanol. As a control 
treatment all cells were treated with an equivalent 50/50 
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mixture of water/ethanol. Tetrotodoxin (TTX) was obtained 
from Tocris and a stock of 10 mM was prepared in sterile 
water.
Antibodies
A polyclonal antibody to nNav1.5 was produced in a simi-
lar manner as described previously (Chioni et al. 2005). 
Two rabbits were injected with a peptide derived from 
the published sequence of the nNav1.5 ion channel D1/
S3:S4 extracellular loop (peptide sequence YVSENIKL-
GNLSALRC) using the Covalab polyclonal antibody 
service. Peptides were purified by RP-HPLC and stored 
dry at −20 °C. Identity of the peptide was confirmed by 
MALDI-TOF. The purity was estimated to be not less than 
80 %. Rabbit anti-serum was generated towards the peptide 
covalently linked to maleimide-activated key-hole limpet 
heamacyanin (KLH) for improved immunogenicity. The 
C-terminal cysteine (not present in the nNav1.5 sequence) 
allowed coupling of the peptides to maleimide-activated 
KLH. Rabbits were immunised by injection with peptide–
KLH conjugates mixed with Freund’s incomplete adjuvant. 
Subsequent booster injections were performed on days 21, 
42 and 63. Animals were killed and bled on day 88. Anti-
bodies were purified from the rabbit sera by immunopu-
rification against the above peptide. The immunoaffinity 
column was prepared by coupling the peptide to 1 ml of 
activated Sepharose beads and purification from 5 ml of 
serum. The purified antibody was subsequently tested by 
ELISA against the immunixing peptide. The purified anti-
body concentration was 378.6 μg/ml. Production of the 
sigma-1 receptor antibody in rabbits was described previ-
ously (Palmer et al. 2007).
Gene silencing
A sigma-1 gene silencing vector was constructed using 
the pSilencer RNAi vector (Ambion) as described previ-
ously, which affects both sigma-1 receptor mRNA and 
protein levels without affecting basal gene expression lev-
els (Palmer et al. 2007). As a control, a sigma-1 receptor 
RNAi randomised sequence was constructed in pSilencer. 
Transfection was accomplished using Lipofectamine 2000 
(Invitrogen) and Opti-MEM (Life Technologies). Transfec-
tion efficiency was verified by cotransfecting a green fluo-
rescence protein-expressing plasmid (pHr-GFP). Silencing 
efficiency was quantified by protein extraction from cul-
tures 4 days post-transfection and Western blotting 5 μg of 
total cell protein onto nitrocellulose followed by detection 
using a sigma-1 receptor-specific antibody and an anti-α-
actinin antibody (Sigma-Aldrich) as control for nonspecific 
effects on gene expression. Silencing efficiencies of >60 % 
were usually obtained.
Proliferation assay
Freshly harvested cells were diluted to 10,000 cells/ml in 
growth media and seeded into 96-well plates at 100 μl per 
well. Following an overnight incubation the media was 
removed and replaced with 100 μl of growth media con-
taining SKF10047, N-methy-DMT or control treatment. 
The cells were incubated for 4 days at 37 °C and cell prolif-
eration was measured by adding 10 μl of cell counting rea-
gent (cc-8 Sigma-Aldrich) and incubation for 3 h at 37 °C. 
Subsequently the absorbance at 450 nm was measured with 
a Floustar Omega plate reader using wells with growth 
media and cell counting reagent only as a blank control.
Adhesion assay
Cells were seeded at 1.5 × 106 cells into 100-mm culture 
dishes in 10 ml of growth media. The cells were incubated 
overnight and the media was removed and replaced with 
fresh media containing sigma-1 drugs or control treatment. 
Following 24 h treatment at 37 °C, the cells were washed 
with PBS and incubated with PBS containing 10 mM 
EDTA for 15 min at 37 °C. The detached cells were col-
lected by centrifugation at 1200 rpm for 5 min and the pel-
let was resuspended in 2 ml of growth media. The cells 
were counted and diluted to a concentration of 5 × 105 
cells per ml. To 1 ml of cell suspension 3 μl of calcein, AM 
(Invitrogen 1 mM stock in DMSO), was added and incu-
bated at 37 °C for 30 min. The cells were centrifuged twice 
and washed with growth media at 1200 rpm for 5 min and 
resuspended in 1 ml of growth media. Cells were plated 
into 96-well plates (100 μl per well) precoated with colla-
gen. Plates were coated in a solution containing 125 μg/ml 
of collagen protein in PBS for 1 h at 37 °C before washing 
thrice with PBS and once with DMEM. Afterwards, non-
adherent cells were removed by washing the wells three 
times with PBS, swirling the contents and inverting them 
onto filter paper. Finally 100 μl of phosphate-buffered 
saline (PBS) was added to each well and fluorescence was 
measured using a Fluostar Omega plate reader (excitation, 
480 nm; emission, 520 nm) using wells containing PBS 
alone as a blank control.
Transverse migration assay
The assay was performed using 8-μm-pore, 24-well poly-
carbonate transwell filters (Corning Inc., UK). Twenty-four 
hours prior to the assay the cells were starved by grow-
ing them in serum-free medium. The cells were harvested 
using PBS containing 10 mM EDTA and resuspended in 
serum-free media at 2 × 106 cells/ml. The bottom chamber 
contained 500 μl of growth medium. To the top chamber, 
100 μl of cells was added with or without sigma-1 drugs. 
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The plates were incubated at 37 °C in a CO2 incubator 
for 24 h. The media from the top chamber was aspirated 
and the chamber washed with PBS. The bottom chamber 
was aspirated and washed with PBS and then replaced 
with 500 μl of PBS-EDTA containing 10 μM calcein-AM 
and incubated at 37 °C in a CO2 incubator for 1 h. Subse-
quently, the plate was shaken for 10 min at room tempera-
ture. The top chamber was removed and the plate was read 
at 480 nm excitation, 520 nm emission.
Patch clamp recording
Experiments were performed on MDA-MB-468 cells that 
had not been electrophysiologically characterised before. 
Details of the patch pipettes, solutions and the whole-
cell recording protocols have been described previously 
(Grimes et al. 1995; Laniado et al. 1997; Fraser et al. 
2005). Patch pipettes (tip resistances, ~5 MΩ) were filled 
with a solution designed to block the outward K+ currents; 
the composition was as follows (in mM): NaCl 5, CsCl 
145, MgCl2 2, CaCl2 1, HEPES 10 and EGTA 11, adjusted 
to pH 7.4 with 1 M CsOH. The estimated intracellular free 
calcium concentration was ~15 nM (Laniado et al. 2001). 
Cells were triturated 1–2 h prior to patching and whole-cell 
membrane currents were recorded from cells that appeared 
‘isolated’ in culture, using an Axopatch 200B amplifier 
(Axon Instruments, CA, USA). Analogue signals were 
filtered at 5 kHz using a lowpass Bessel filter and series 
resistance errors were compensated by ~95 %. Electro-
physiological signals were sampled at 50 kHz and digit-
ised using an interface (Digidata 1200). Data acquisition 
and analysis of whole-cell currents were performed using 
pClamp software (Axon Instruments). A holding potential 
of −100 mV was applied. Standard voltage-clamp proto-
cols were used to study the electrophysiological character-
istics of the Na+ currents. Tetrodotoxin was bath applied 
and effects on VGSCs were studied using a single-step 
voltage pulse protocol (from −100 to −10 mV for 10 ms), 
repeated at 10-s intervals.
Western blotting
Protein samples (concentration, 1 mg/ml) were mixed with 
SDS sample buffer (Sigma-Aldrich), heated to 95 °C for 
5 min and 5 μg of protein were loaded per lane and sepa-
rated on acrylamide 4–20 % gradient Tris–glycine minigels 
(Invitrogen). The proteins were transferred to nitrocellu-
lose membrane for 2 h (for sigma-1 receptor) or 6 h (for 
nNav1.5) at 4 °C; transfer was verified using Ponceau red 
(Sigma-Aldrich). Blots were ‘blocked’ with a solution con-
taining 2.5 % skimmed milk and 2.5 % bovine serum albu-
min (BSA) in PBS overnight at 4 °C before probing with 
specific antibodies. The antibodies were diluted to 1 μg/
ml in PBS containing 0.1 % Tween (PBST) with 0.5 % 
skimmed milk and 0.5 % BSA and incubated with the blot 
for 4 h at room temperature. Following four 10-min washes 
with PBST (with constant agitation) at room temperature, 
the blots were incubated with anti-rabbit horseradish perox-
idase-conjugated secondary antibodies (at the manufactur-
ers’ suggested concentrations) as appropriate and diluted in 
PBST with 0.5 % skimmed milk and 0.5 % BSA for 2 h at 
room temperature. The blots were again washed as before 
and then developed with an enhanced chemiluminescence 
Western blot kit (Amersham). All blots were quantified 
using the NIH IMAGE programme.
Immunocytochemistry
Cells were seeded into 35-mm dishes containing glass 
coverslips coated with poly-l-lysine at 1 × 106 cell cells/
dish. Following an overnight incubation at 37 °C wells 
were washed three times with HBSS. Cells were fixed with 
3 % paraformaldehyde at room temperature for 12 min and 
subsequently washed three times with PBS. Cells were 
permeabilised with 0.1 % saponin for 10 min at room tem-
perature followed by a further three washes with PBS. The 
cells were blocked with 5 % BSA in PBS for 1 h. Primary 
antibodies to sigma-1 or nNav1.5 were added overnight 
at a concentration of 5 μg/ml at 4 °C. Control antibodies, 
which included purified rabbit IgG, were also used. Follow-
ing three washes with PBS containing 0.05 % Tween, the 
cells were stained with an anti-rabbit antibody with flouro-
chromes attached overnight at 4 °C. Following a further 
three washes, the cells were drained of liquid and mounted 
with VectorShield and analysed by florescence microscopy.
Surface expression of nNav1.5
Surface expression of nNav1.5 was determined by seed-
ing cells into 24-well plates coated with poly-l-lysine at 
5 × 105 cells cells/well. Following an overnight incubation 
at 37 °C wells were washed three times with Hanks-buff-
ered saline solution (HBSS) and subsequently 5 μg rabbit 
anti-nNav1.5 antibody in 1 ml of HBSS containing 5 % 
BSA was added for 1 h at 37 °C. The cells were washed 
three times with HBSS and incubated with a 1/100 dilution 
of anti-rabbit IgG Texas Red (Sigma-Aldrich) in 1 ml of 
HBSS containing 5 % BSA for 1 h at 37 °C. The cells were 
washed three times in HBSS and then fluorescence was 
measured using a Floustar Omega plate reader.
Immunoprecipitation
Protein extracts were prepared from cells using RIPA 
buffer (Triton-X at 1 %) containing a proteinase cocktail 
(Roche) and adjusted to a concentration of 1 mg/ml. A 
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mouse anti-Nav1.5 was added at 1 μg/ml for 4 h at 4 °C. 
Subsequently beads with protein-A were added for 4 h at 
4 °C. Immunoprecipitation washes were carried out with 
a kit from Pierce utilising spin columns. Following pull-
down and washing of the beads, the samples were mixed 
with SDS-PAGE sample buffer (Sigma) and loaded onto 
SDS-PAGE gels as described previously. As controls, 
the immunoprecipitation was performed in the absence 
of immunoprecipitation antibody and with beads with-
out protein A attached (to verify nonspecific binding of 
proteins).
Data analysis
Statistical significance was analysed by one-way ANOVA. 
Differences were taken as significant for P < 0.05.
Results
Initial characterisation
Sigma-1 receptor protein expression was investigated in 
MDA-MB-468, MDA-MB-231 and MDA-MB-453 cells 
(Fig. 1a). Both MDA-MB-231 and MDA-MB-468 cells 
are known to be highly invasive/metastatic both in vitro 
and in vivo. We therefore decided to investigate the role 
of the sigma-1 receptor on in vitro metastasis. Previously, 
sigma-1 receptor silencing constructs were validated in 
MDA-MB-231 cells (Palmer et al. 2007). These vectors 
were transfected into MDA-MB-468 and MDA-MB-231 
cells and after 48 h the level of mRNA silencing was 
determined in comparison to a control vector (Fig. 1a, b). 
Transfection efficiency was determined by cotransfection 
of a plasmid expressing GFP (pHr-GFP). For transfec-
tion efficiency of >70 %, the silencing efficiency ranged 
between 62 and 86 %. nNav1.5 protein and functional 
expression in MDA-MB-231 cells has been shown previ-
ously (Fraser et al. 2005). Here, we extended these stud-
ies to MDA-MB-468 cells. nNav1.5 protein expression was 
detected in the MDA-MB-468 cell line at the expected size 
of ~200 kDa (Fig. 1c). Functional expression was con-
firmed in 57 % (26 out of 46) cells tested (Fig. 1d, e). Peak 
current density was 2.0 ± 0.3 pA/pF (n = 26). Removing 
the Na+ in the bathing solution completely eliminated the 
inward current (n = 3; not shown). The inward current was 
blocked by TTX in a dose-dependent manner (Fig. 1f). The 
dose dependence was consistent with the VGSC being TTX 
resistant, as would be expected for nNav1.5 (Fraser et al. 
2005). Previously we demonstrated that the non-metastatic 
BCa cell line (MCF10A) expressed a lower amount of 
sigma-1 receptor when compared to the metastatic cell line 
MDA-MB-231 (Aydar et al. 2006).
Immunolocalisation
Cellular localisation of nNav1.5 and sigma-1 receptors in 
MDA-MB-231 cells has been previously reported (Fraser 
et al. 2005; Palmer et al. 2007). We extended these studies 
to MDA-MB-468 cells (Fig. 2). The sigma-1 receptor was 
observed throughout the cytoplasm and at or close to the 
plasma membrane. nNav1.5 protein also was visualised in 
the cytoplasm and also at or close to the plasma membrane, 
although the majority of staining appeared to be the latter. 
On the other hand, when the cells were not permeabilised, 
nNav1.5 staining was extremely weak (data not shown). 
These observations are consistent with the electrophysiol-
ogy and the nNav1.5 antibody binding to an extracellular 
domain.
Proliferation and migration
Although sigma ligands have been reported to affect cel-
lular proliferation, in the vast majority of cases this was 
likely due to the action of the ligands used having a mixed 
specificity for both sigma-1 and sigma-2 receptors (Aydar 
et al. 2004). The effects of sigma-1 drugs on the prolifera-
tion of MDA-MB-231 and MDA-MB-468 cells were deter-
mined here using agents specific for sigma-1. Cells were 
treated with SKF10047 or 5-methyl-DMT at concentrations 
of 50, 20, 5 and 1 μM (Fig. 3). No significant difference 
was observed between drug-treated cells and untreated 
controls even after 4 days of incubation. Additionally no 
change in viability was detected when cells were stained 
with trypan blue.
An important factor in metastasis is the ability of cells 
to migrate from the site of the primary tumour to form 
secondary cancer lesions. The effects of sigma-1 drugs on 
the migration of MDA-MB-231 and MDA-MB-468 cells 
were determined. Cells were treated with SKF10047 or 
5-methyl-DMT at concentrations of 50, 20, 5 and 1 μM 
(Fig. 4). No significant difference was observed between 
sigma-1 drug-treated cells and untreated cells.
It was concluded that sigma-1 receptors do not play a 
significant role in the proliferative activities or migration of 
MDA-MB-231 and MDA-MB-468 cells.
Adhesion
The ability of cancer cells to detach from a primary tumour 
and subsequently re-attach to other tissues is an important 
determinant of their metastatic potential. The effects of 
sigma-1 drugs on adhesion of MDA-MB-231 and MDA-
MB-468 cells were thus determined. Cells were treated 
with SKF10047 or 5-methyl-DMT at concentrations of 50, 
20, 5 and 1 μM (Fig. 5). SKF10047 at concentrations of 20 
and 50 μM reduced the adhesion of MDA-MB-468 cells 
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by 35 and 40 %, respectively (Fig. 5a; P < 0.05; n = 5). 
Similarly, treatment with 5-methyl-DMT at concentrations 
of 20 and 50 μM reduced the adhesion of MDA-MB-468 
cells by 46 and 52 %, respectively (Fig. 5b; P < 0.05; 
n = 5). Similar results were obtained for MDA-MB-231 
cells with SKF10047, as reported previously (Fig. 5e, f) 
(Palmer et al. 2007). Cellular adhesion was determined in 
MDA-MB-468 cells also following sigma-1 receptor gene 
silencing. Compared with the control silencing construct, 
a significant reduction in adhesion of 30 % was observed 
(P < 0.05; n = 5) (Fig. 5c). Additionally, 50 μM SKF10047 
had no effect on the adhesion of sigma-1 receptor silenced 
MDA-MB-468 cells (Fig. 5c). Similar results were obtained 
for MDA-MB-231 cells (Fig. 5g). It was concluded that the 
effect of SKF10047 on cellular adhesion occurred through 
the sigma-1 receptor and not through some other non-spe-
cific mechanism.
The effects of SKF10047 on cellular adhesion were also 
studied in relation to VGSC activity (Fig. 5d, h). For the 
MDA-MB-468 cell line, 20 μM SKF10047 elicited 45 % 
reduction in adhesion while 10 μM TTX elicited a 62 % 
reduction. For the MDA-MB-231 cell line, similar con-
centrations of SKF10047 and TTX elicited 37 and 55 % 
reduction in adhesion, respectively. These effects were 
Fig. 1  Expression of sigma-1 receptors and VGSCs in BCa cell lines. 
a MDA-MB-468, MDA-MB-468 control siRNA, MDA-MB-468 
sigma-1 receptor siRNA, MDA-MB-231 and MDA-MB-453. Sizes 
of molecular weight markers in KDa are shown to the left of the 
blot. Expected sizes of α-actinin and sigma-1 receptor proteins are 
indicated to the right of the blot. b Silencing of sigma-1 receptors 
in MDA-MB-231 cells. Sigma-1 receptor siRNA, sigma-1 receptor 
control siRNA. Expected sizes of α-actinin and sigma-1 receptor pro-
teins are indicated to the right of the blot. c Expression of nNav1.5 
in MDA-MB-468 cells. nNav1.5 probed with a specific antibody to 
nNav1.5. Sizes of molecular weight markers in KDa are shown to the 
left of the blot. d Current traces showing activation of the VGSC in 
MDA-MB-468 cells over the −80 to 0 mV range. For clarity only 
every second trace is shown. e Current-voltage relationship for the 
VGSC expressed in the MDA-MB-468 cells (n = 9). f Dose-depend-
ent effect of tetrodotoxin (TTX) on the current expressed in MDA-
MB-468 cells (n = 5 for both)
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statistically significant (P < 0.05, n = 6) and raised the pos-
sibility that VGSC activity could be involved in the action 
of SKF10047 since it is clear that the reduction in adhesion 
seen by application of SKF10047 was in theory able to be 
reduced further (e.g., by sigma-1 SiRNA). Given that appli-
cation of TTX reduces the adhesion to a greater extent than 
SKF10047, this gives weight to our theory that the sigma-1 
receptor is acting through modulation of nNav1.5 since dual 
application of SKF10047 and sigma-1 receptor SiRNA did 
not elicit a significantly greater reduction in adhesion com-
pared to single treatments.
Sigma‑1—VGSC (nNav1.5) interaction
Sigma-1 receptors have been demonstrated to modulate 
Nav1.5 channels in cardiomyocyes or when heterologously 
coexpressed in HEK-293 cells (Johannessen et al. 2011). 
In an initial attempt to determine whether the effect of 
sigma-1 receptor drugs on the adhesion of MDA-MB-231 
and MDA-MB-468 cells involved VGSC activity, we 
performed a number of experiments with a combination 
of treatments with SKF10047 and the polyclonal anti-
body to nNav1.5 which is known to be a channel blocker 
(Chioni et al. 2005). Thus, the ability of the “blocking” 
polyclonal antibody to nNav1.5 to reduce the adhesion of 
MDA-MB-231 and MDA-MB-468 cells was first deter-
mined (Fig. 6). Cells were incubated with 100, 20, 5, 1 and 
0.2 ng/ml of antibody for 24 h and then cellular adhesion 
was determined. Significant, dose-dependent reduction in 
adhesion was observed for MDA-MB-468 cells with 100, 
20 and 5 ng/ml antibody causing a reduction of 45, 40 
and 29 %, respectively (P < 0.05 for all; n = 5; Fig. 6a). 
Incubation of cells with a control IgG antibody at the same 
concentrations had no effect (Fig. 6a). Additionally, pre-
incubation of the nNav1.5 polyclonal antibody with an 
excess of the immunisation peptide blocked the effect of 
the antibody (Fig. 6a). The effect on adhesion of combi-
nation treatments with SKF10047 (50 μM) and nNav1.5 
antibody (20 ng/ml) was also determined. No significant 
difference was observed in the adhesiveness of MDA-
MB-468 cells treated with SKF10047 or nNav1.5 antibody 
alone or a combination of both (Fig. 6c). Finally, silencing 
the sigma-1 receptor in MDA-MB-468 cells also reduced 
the adhesion and application of nNav1.5 antibody (20 ng/
ml) to the cells had no further effect (Fig. 6e). Comparable 
results were obtained for MDA-MB-231 cells (Fig. 6d, f). 
These results were consistent with nNa1.5 playing a sig-
nificant role in the mechanism of action of the sigma-1 
receptor.
We then demonstrated that nNav1.5 is in a complex 
with the sigma-1 receptor in both MDA-MB-231 and 
MDA-MB-468 cells (Fig. 7a, b). Immunoprecipitation 
was utilised, protein extracts were prepared from the two 
cell lines and a mouse anti-Nav1.5 antibody was used to 
pull down the Nav1.5 protein and any proteins in a com-
plex with the Nav1.5 protein. The immuneprecipitated 
complexes were separated by SDS-PAGE and transferred 
by Western blot to nitrocellulose membranes. The blots 
were probed with antibodies to the sigma-1 receptor (pro-
duced in rabbits). Following development bands at the 
expected size of the sigma-1 were visualised indicating 
the Nav1.5 in these cells is in a complex with the sigma-1 
receptor.
In addition, the effects of SKF10047 and sigma-1 recep-
tor gene silencing on the surface expression of nNav1.5 
were determined (Fig. 7c, d). Treatment of MDA-MB-468 
and MDA-MB-231 cells with 50 μM SKF10047 for 24 h 
caused a 40 and 31 % reduction in the plasma membrane 
expression of nNav1.5 protein, respectively. For 50 μM 
5-methyl-DMT, there was 52 and 44 % reduction in expres-
sion, respectively. Similar results were obtained from 
sigma-1 receptor-silenced cells. Thus, a reduction of 46 
and 47 % in the cell-surface expression of nNav1.5 protein 
was observed upon sigma-1 silencing in MDA-MB-468 
Fig. 2  Immunocytochemical localisation and analysis of nNav1.5 
and sigma-1 receptor expression in MDA-MB-468 cells. Total mag-
nification is shown to the left of the images. a Permeabilised MDA-
MB-468 cells probed with sigma-1 receptor antibody. b Permeabi-
lised MDA-MB-468 cells probed with antibodies to nNav1.5
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and MDA-MB-231 cells, respectively. Finally, treatment 
of sigma-1-silenced cells with SKF10047 did not produce 
any further effect. It was concluded that sigma-1 receptor 
modulated (up-regulated) the plasma membrane expression 
of nNav1.5 in BCa cells.
Discussion
This article attempts to tie together several pieces of 
experimental evidence and provide a plausible explana-
tion for the mechanism through which sigma-1 receptor 
Fig. 3  Lack of effect of 
sigma-1 drugs on proliferation 
of MDA-MB-468 (a, b) and 
MDA-MB-231 cells (c, d). 
Cells treated with SKF10047 (a, 
c) or 5-methyl-DMT (b, d) at 
concentrations of 50, 20, 5 and 
1 μM as indicated. Proliferation 
was quantified as absorbance at 
450 nm
Fig. 4  Lack of effect of 
sigma-1 drugs on migra-
tion of MDA-MB-468 (a, b) 
and MDA-MB-231 cells (c, 
d). Cells were treated with 
SKF10047 (a, c) or 5-methyl-
DMT (b, d) at concentrations of 
50, 20, 5 and 1 μM as indicated. 
Migrated cells were labelled 
with calcein-AM. Migration 
was quantified as the fluorescent 
emission measured at 520 nm
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drugs are able to alter the metastatic behaviour of BCa 
cells. It has been established by many researchers that 
sigma-1 receptors are able to modulate ion channels 
in a variety of cell types (Aydar et al. 2002; Lupardus 
et al. 2000; Johannessen et al. 2011). In particular, the 
sigma-1 receptor was found to regulate the current den-
sity of VGSCs in MDA-MB-231 cells (Balasuriya et al. 
2012). Here, we have demonstrated that modulation of 
sigma-1 receptors in BCa cell lines can partially affect 
their metastatic behaviour (with respect to adhesive-
ness) and that this effect could be mediated via func-
tional nNav1.5 expression. It is now well established 
that VGSC (nNav1.5) up-regulation occurs in metastatic 
BCa cells and this promotes the cells metastatic behav-
iour in vitro and in vivo (Fraser et al. 2005; Bracken-
bury et al. 2007; Nelson et al. 2015). Although the exact 
mechanism of sigma-1 receptor modulation of ion chan-
nels is not clear, it has been suggested that sigma-1 
receptors form a complex with VGSCs (Balasuriya et al. 
2012). Given these facts, our hypotheses are (1) that 
sigma-1 receptors form a functional signalling complex 
with VGSCs in BCa cell lines and (2) that, through this 
complex, sigma-1 receptors are able to modulate VGSC 
plasma membrane expression and hence the cells’ meta-
static behaviour.
We have previously reported on the expression and 
activity of sigma-1 receptors in MDA-MB-231 cells 
(Palmer et al. 2007). We now provide evidence for the 
expression of sigma-1 receptors in two further BCa cell 
lines: MDA-MB-468 and MDA-MB-453. Further to this, in 
MDA-MB-468 cells, sigma-1 receptor protein expression 
was found to be localised throughout the cell, except within 
the nucleus, consistent with previous studies on MDA-
MB-231 cells (Palmer et al. 2007). In addition, functional 
expression of nNav1.5 channels in MDA-MB-231 cells has 
been reported (Fraser et al. 2005). We now provide both 
immunocytochemical and electrophysiological evidence 
that the MDA-MB-468 cell line (when grown in 5 % FBS) 
also expresses a TTX-resistant VGSC, most likely to be 
nNav1.5.
Two drugs (SKF1047 and 5-methyl-DMT) with sig-
nificant selectivity for sigma-1 receptors over sigma-2 
receptors showed no observable effect on the prolifera-
tion of the MDA-MB-231 and MDA-MB-468 cells. These 
results are consistent with earlier suggestions that many 
of the anti-proliferative effects of sigma drugs are due to 
binding to the sigma-2 receptor (Aydar et al. 2004). Both 
drugs also showed no effect on the migration of MDA-
MB-231 and MDA-MB-468 cells suggesting that sigma-1 
receptors do not play a significant role in cellular motility. 
Fig. 5  Effect of sigma-1 drugs and sigma-1 receptor gene silenc-
ing on adhesion of MDA-MB-468 (a–d) and MDA-MB-231 cells 
(e–h). Cells were treated with SKF10047 (a, e) or 5-methyl-DMT (b, 
f) at concentrations of 50, 20, 5 and 1 μM, as indicated. Following 
sigma-1 receptor gene silencing, cellular adhesion was determined in 
comparison to cells transfected with a control silencing construct (c, 
g). Additionally, adhesion of control and sigma-1 receptor silenced 
cells was determined following a 24-h treatment with SKF10047. A 
comparison of the effect of 10 μM TTX or 50 μM SKF10047 was 
made (d, h). Experiments with a significant difference from the con-
trol treatment are marked with an asterisk (P < 0.05). Adhesion was 
quantified as the fluorescence emission measured at 520 nm
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This result was rather surprising and would require fur-
ther exploration in light of the fact that 4-IBP, another 
sigma-1 receptor agonist, was found to decrease the 
migration of glioblastoma cells (Megalizzi et al. 2007). 
Previously, SKF10047 was found to promote the detach-
ment of MDA-MB-231 cells plated on collagen in a ‘sin-
gle cell’ adhesion assay (Palmer et al. 2007, 2008). In 
the present study, a florescence-based ‘population’ adhe-
sion assay was used that measured the ability of cells to 
attach to collagen-coated plates. The results showed both 
SKF10047 and DMT as well as sigma-1 receptor silenc-
ing significantly reduced adhesion of both BCa cell 
lines. In addition, application of SKF10047 to cells with 
sigma-1 receptor silenced did not produce any effect. This 
Fig. 6  Combination treatments with sigma-1 drugs and nNav1.5 
blocking antibody on adhesion of MDA-MB-468 (a, c, e) and 
MDA-MB-231 cells (b, d, f). The ability of a polyclonal antibody to 
nNav1.5 to reduce the adhesion of MDA-MB-468 and MDA-MB-231 
cells was determined (a, b). Cells were incubated with 100, 20, 5, 
1 and 0.2 ng/ml of nNav1.5 polyclonal antibody (n = 5). Control-
a (Con-a) consisted of 100 ng/ul of rabbit IgG in PBS containing 
azide. Control-b (Con-b) consisted of 20 ng/ml of nNav1.5 antibody 
pre-incubated with 100 ug/ml of nNav1.5 peptide for 1 h at room 
temperature. The effect on adhesion on a combination of treatments 
with SKF10047 (50 μM) and nNav1.5 polyclonal antibodies (20 ng/
ml) was determined (c, d). The effect on adhesion on a combination 
of sigma-1 receptor gene silencing and nNav1.5 polyclonal antibod-
ies (20 ng/ml) was determined (e, f). Experiments with a significant 
difference from the respective control treatment are marked with 
an asterisk (P < 0.05). Adhesion was quantified as the fluorescence 
emission measured at 520 nm
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suggested strongly that the sigma-1 receptor controlled 
the adhesiveness. The VGSC blocker TTX and a poly-
clonal antibody blocking nNav1.5 activity also reduced 
the adhesion of both BCa cell lines used. Systematic com-
bination treatments involving TTX, nNav1.5 antibody, 
SKF10047 and sigma-1 receptor gene silencing suggested 
consistently that the sigma-1 modulation of adhesion 
occurred through the VGSC pathway. Possible interaction 
between nNav1.5 and sigma-1 receptor was investigated. 
Immunoprecipitation showed for both MDA-MB-231 
and MDA-MB-468 cell lines that nNav1.5 and sigma-1 
receptor were in a protein complex. This is in agreement 
Fig. 7  Immunoprecipitation of the sigma-1 receptor by nNav1.5 and 
effect of SKF10047 and sigma-1 gene silencing on surface expression 
of nNav1.5 in the MDA-MB-468 (a, c) and MDA-MB-231 cell line 
(b, d). a, b Cells were grown for 48 h and protein was extracted as 
detailed in the methods. Protein extracts were mixed with an antibody 
to Nav1.5 (anti-mouse Nav1.5) for 2 h. Subsequently Sepharose beads 
with protein A attached were added for 2 h. The beads were sedi-
mented and washed three times. Subsequently, the beads were resus-
pended in SDS-sample loading buffer and heated at 95 °C for 5 min. 
The samples were separated on polyacrylamide gel electrophoresis 
and the proteins were transferred to nitrocellulose membranes and 
probed with an antibody to the sigma-1 receptor (anti-rabbit Sigma-1 
receptor). Lanes Control reactions without a Nav1.5 immunopre-
cipitation antibody; 3 μl of immunoprecipitation extract; 10 μl of 
immunoprecipitation extract; whole cell extract; immunoprecipitation 
with beads without protein A. Sizes of molecular weight markers in 
KDa are shown to the right of the blots. c, d Cells were seeded into 
24-well dishes coated with poly-l-lysine. Cells were treated with 50 
uM SKF10047 for 24 h. Subsequently, the cells were stained for sur-
face expression of nNav1.5 followed by an anti-rabbit IgG antibody 
labelled with Texas Red. The results were quantified in a fluorescence 
plate reader (n = 5). Following the assay cells were labelled with 
calcein-AM in order to verify that each dish contained equivalent 
numbers of cells. A similar experiment was performed for cells trans-
fected with a sigma-1 receptor silencing construct for 48 h compared 
to those cells transfected with a control plasmid
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with past findings using atomic force microscopy show-
ing that sigma-1 receptors and Nav1.5 form a complex 
with a fourfold symmetry (Balasuriya et al. 2012). It is 
not yet known whether the interaction between sigma-1 
receptor and nNav1.5 is direct (i.e., protein–protein) or 
indirect (e.g., involving a small intermediary molecule). 
Neverthelss, one consequence of this association appeared 
to be promotion of plasma membrane expression of 
nNav1.5 and adhesion to the substrate. Interestingly, both 
such effects are known to be controlled by the VGSC beta 
subunit(s) (Chioni et al. 2009).
Conclusions and future perspectives
We have found significant evidence that sigma-1 recep-
tors are expressed in a number of metastatic BCa cell 
lines and that in both MDA-MB-231 and MDA-MB468 
cells sigma-1 receptor increases cellular adhesion to the 
substrate through a functional interaction with nNav1.5 
channels. This appears to involve a close physical inter-
action between sigma-1 receptors, possibly in macromo-
lecular complex within the cells. Our data add weight to 
the model in which the sigma-1 receptor is “silent” under 
normal physiological conditions, whereas in disease, 
sigma-1 receptors behave as a “chaperone” that binds and 
traffics client protein(s) so as to modulate the pathophysi-
ology (Su et al. 2010). In the case of MDA-MB-231 and 
MDA-MB-468 cells, the sigma-1 receptor translocates 
nNav1.5 protein to the plasma membrane and reduces 
adhesion, thereby enhancing the metastatic potential. 
These effects are consistent with the interaction occurring 
early in metastasis and, indeed, House et al. (2010) have 
shown that VGSC expression is upstream of a network of 
genes controlling the invasiveness in colon cancer. Stud-
ies of Kv11.1 (hERG) and sigma-1 receptor are also con-
sistent with the idea of sigma-1 receptor behaving either 
like a chaperone and/or a channel regulatory auxillary 
subunit through protein–protein interaction (Crottes et al. 
2011; Kinoshita et al. 2012). This hypothesis was fur-
ther strengthened by a recent report showing that cocaine 
exposure induces a persistent protein–protein association 
between the sigma-1 receptor and Kv1.2 channel. This 
phenomenon was associated with a redistribution of both 
proteins from the intracellular compartments to the plasma 
membrane (Kourrich et al. 2013).
The significant involvement of the sigma-1 receptor in 
VGSC expression/activity may have wide-reaching clinical 
implications since VGSCs, and in particular nNav1.5, have 
already been proposed as a novel anti-metastatic target in 
a range of cancers (Fraser et al. 2014; Onkal and Djamgoz 
2009; Djamgoz and Onkal 2013).
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